Bio-Techne Corporation’s Stock Price Dips to $60.89, Recording a 3.09% Decline: Is it Time to Buy?

Bio-Techne Corporation (TECH)

60.89 USD -1.94 (-3.09%) Volume: 1.52M

Discover the latest on Bio-Techne Corporation’s stock price, currently at 60.89 USD, experiencing a trading session drop of 3.09%. With a trading volume of 1.52M and a year-to-date decrease of 15.47%, explore the factors influencing TECH’s stock performance in the biotechnology sector.

Latest developments on Bio-Techne Corporation

Leading up to today’s movements in Bio Techne Corp stock price, shareholders have seen a steady 8.3% compound annual growth rate over the last five years. Recently, Evercore ISI Group initiated coverage of Bio-Techne (NASDAQ:TECH) with an outperform recommendation, setting a $75 target for the stock. This assessment by 6 analysts highlights Bio-Techne as a premium growth asset with a strong market position and promising future outlook, further bolstering investor confidence in the company’s potential for continued success.

Bio-Techne Corporation on Smartkarma

Independent analysts on Smartkarma, such as Baptista Research, have been covering Bio Techne Corp and providing bullish insights on the company’s performance. In their research reports, analysts highlighted Bio-Techne Corporation’s strong revenue growth in the second quarter of fiscal year 2025, driven by contributions from biopharma end markets and advancements in areas like ExosomeDx and spatial biology. The company reported a 9% year-over-year increase in revenue, reaching $297 million in total sales, with significant orders from large pharmaceutical companies for GMP reagents and protein analytical implementations.

Furthermore, Baptista Research delved into Bio-Techne Corporation’s market position and product expansion in diagnostics and spatial biology in another report on Smartkarma. The analysts noted a 4% year-over-year organic revenue growth in the first quarter of Fiscal Year 2025, attributing the solid performance to the stabilization of biopharma end markets and successful execution in areas like cell and gene therapy. Baptista Research also conducted an independent valuation of the company using a Discounted Cash Flow (DCF) methodology to assess potential future price influences for investors.

A look at Bio-Techne Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Bio Techne Corp seems to have a promising long-term outlook. The company scores well in momentum, indicating strong market performance and investor interest. Additionally, Bio Techne Corp scores evenly across value, dividend, and growth factors, suggesting a stable financial position and potential for future growth. However, the company scores lower in resilience, which may indicate some vulnerability to economic downturns or industry challenges.

Bio Techne Corp is a biotechnology company that focuses on developing, manufacturing, and selling a variety of biotechnology products and clinical diagnostic controls. Specializing in proteins, cytokines, growth factors, immunoassays, and small molecules, the company plays a crucial role in advancing research and diagnostics in the healthcare industry. With its solid scores in various aspects, Bio Techne Corp appears to be well-positioned for continued success in the biotechnology market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma